ABSTRACT
Recombinant adenoviral vector (rAd)-based vaccines are currently being developed for several infectious diseases and cancer therapy, but pre-existing seroprevalence to such vectors may prevent their use in broad human populations. In this study, we investigated the potential of low seroprevalence non-human primate rAd vectors to stimulate cellular and humoral responses using HIV/SIV Env glycoprotein (gp) as the representative antigen. Mice were immunized with novel simian or chimpanzee rAd (rSAV or rChAd) vectors encoding HIV gp or SIV gp by single immunization or in heterologous prime/boost combinations (DNA/rAd; rAd/rAd; rAd/NYVAC or rAd/rLCM), and adaptive immunity was assessed. Among the rSAV and rChAd tested, rSAV16 or rChAd3 vector alone generated the most potent immune responses. The DNA/rSAV regimen also generated immune responses similar to the DNA/rAd5 regimen. rChAd63/rChAd3 and rChAd3 /NYVAC induced similar or even higher levels of CD4+ and CD8+ T-cell and IgG responses as compared to rAd28/rAd5, one of the most potent combinations of human rAds. The optimized vaccine regimen stimulated improved cellular immune responses and neutralizing antibodies against HIV compared to the DNA/rAd5 regimen. Based on these results, this type of novel rAd vector and its prime/boost combination regimens represent promising candidates for vaccine development.
Subject(s)
Adenoviruses, Simian/genetics , Adenoviruses, Simian/immunology , Drug Carriers , Drug Discovery/methods , Genetic Vectors , Viral Vaccines/immunology , Viral Vaccines/isolation & purification , AIDS Vaccines/genetics , AIDS Vaccines/immunology , AIDS Vaccines/isolation & purification , Animals , Antibodies, Viral/blood , CD4-Positive T-Lymphocytes/immunology , CD8-Positive T-Lymphocytes/immunology , Female , Immunoglobulin G/blood , Mice, Inbred BALB C , SAIDS Vaccines/genetics , SAIDS Vaccines/immunology , SAIDS Vaccines/isolation & purification , Vaccines, DNA/genetics , Vaccines, DNA/immunology , Vaccines, DNA/isolation & purification , Vaccines, Synthetic/genetics , Vaccines, Synthetic/immunology , Vaccines, Synthetic/isolation & purification , Viral Vaccines/geneticsABSTRACT
The functional activity of SIVmac251 Rev was altered by introducing amino acid changes inside and chain termination mutations after the Rev response element-binding region (RBR) of the protein. The effects of specific mutations were evaluated by transfecting proviral DNAs into the HeLa cell line and into HeLa cells constitutively expressing either HIV-1 Rev or HTLV-1 Rex proteins. Cell-free supernatants from these transient expression assays were further characterized by infecting CD4-positive lymphoid cell lines H9 and MT-4, the latter abortively infected with HTLV-1, and human peripheral blood mononuclear cells. These results together with the data from cotransfection experiments show that SIV can be attenuated up to 95% by introducing changes into the arginine-rich domain, RBR, of Rev. These recessive mutations were efficiently complemented in trans by HIV-1 Rev, SIV Rev, and HTLV-I Rex proteins. In contrast, the mutants of Rev protein that had a chain termination after RBR were trans-dominant negative and could not be trans-complemented with any of these three regulatory proteins. When additional mutations were inserted into the RBR of these trans-dominantly negative Rev proteins, complementation was obtained again.
Subject(s)
Genes, rev , Mutation , Simian Immunodeficiency Virus/genetics , Virus Replication/genetics , Amino Acid Sequence , Cell Line , Gene Products, rev/genetics , HeLa Cells , Humans , Molecular Sequence Data , SAIDS Vaccines/isolation & purification , Simian Immunodeficiency Virus/physiology , Transfection , Vaccines, Attenuated/isolation & purification , Vaccines, Synthetic/isolation & purificationSubject(s)
AIDS Vaccines/isolation & purification , HIV Infections/prevention & control , Vaccines, DNA/isolation & purification , AIDS Vaccines/administration & dosage , AIDS Vaccines/adverse effects , Adjuvants, Immunologic/administration & dosage , Adjuvants, Immunologic/genetics , Animals , Chemokines/administration & dosage , Chemokines/genetics , Cytokines/administration & dosage , Cytokines/genetics , HIV Infections/immunology , Humans , Primates , SAIDS Vaccines/isolation & purification , Safety , Vaccines, DNA/administration & dosage , Vaccines, DNA/adverse effectsABSTRACT
DermaVir is a novel topical immunisation designed to target Langerhans cells (LC), the epidermal precursors of dendritic cells. LC serve as a vehicle to process and transfer antigens from the skin to T cell areas in the lymphoid organs. The HIV DNA delivered by DermaVir to LC expresses most viral regulatory and structural genes and induces T cell-mediated immune responses with broad specificity. In chronically infected macaques, DermaVir administered with antiretroviral drugs, suppressed viral load rebound after treatment interruption and improved survival. DermaVir is a promising antiretroviral treatment approach with a unique mechanism of action for combination with currently used drugs.
Subject(s)
AIDS Vaccines/isolation & purification , AIDS Vaccines/administration & dosage , AIDS Vaccines/genetics , Administration, Topical , Animals , Antigen Presentation , Biotechnology , HIV Infections/immunology , HIV Infections/therapy , HIV-1/genetics , HIV-1/immunology , Humans , Immunity, Cellular , Langerhans Cells/immunology , Macaca , SAIDS Vaccines/administration & dosage , SAIDS Vaccines/genetics , SAIDS Vaccines/isolation & purification , Simian Immunodeficiency Virus/genetics , Simian Immunodeficiency Virus/immunology , Vaccines, DNA/administration & dosage , Vaccines, DNA/genetics , Vaccines, DNA/isolation & purificationABSTRACT
An infant macaque model was developed to test pediatric vaccine candidates aimed at reducing HIV transmission through breast-feeding. Infant macaques were given multiple immunizations during the first 3 weeks of life with recombinant poxvirus vaccines expressing simian immunodeficiency virus (SIV) structural proteins Gag, Pol, and Env (ALVAC-SIV or modified vaccinia virus Ankara [MVA]-SIV). After repeated daily oral inoculations with virulent SIVmac251 at 4 weeks of age, significantly fewer ALVAC-SIV-immunized infants were infected compared with unimmunized infants. Monkeys not infected after oral challenge in infancy were rechallenged at 16 months of age or older by repeated weekly oral SIV exposure; unimmunized animals were infected after fewer SIV exposures than were animals vaccinated with ALVAC-SIV or MVA-SIV. When infected, ALVAC-SIV- and MVA-SIV-vaccinated animals also had reduced viremia compared with unimmunized animals. The results of these investigations suggest that immunization of human infants with poxvirus-based HIV vaccine candidates may offer protection against early and late HIV infection through breastfeeding.
Subject(s)
SAIDS Vaccines/administration & dosage , Simian Acquired Immunodeficiency Syndrome/prevention & control , Simian Immunodeficiency Virus , Administration, Oral , Animals , Animals, Newborn , Breast Feeding/adverse effects , Female , Gene Products, env/immunology , HIV Infections/prevention & control , HIV Infections/transmission , Humans , Infant, Newborn , Infectious Disease Transmission, Vertical , Macaca mulatta , Poxviridae/genetics , Retroviridae Proteins, Oncogenic/immunology , SAIDS Vaccines/isolation & purification , Simian Acquired Immunodeficiency Syndrome/immunology , Simian Acquired Immunodeficiency Syndrome/virology , Simian Immunodeficiency Virus/immunology , Simian Immunodeficiency Virus/pathogenicity , Vaccines, Attenuated/administration & dosage , Vaccines, Attenuated/isolation & purification , Vaccines, Synthetic/administration & dosage , Vaccines, Synthetic/isolation & purification , Viral Fusion Proteins/immunologyABSTRACT
A cDNA encoding the Simian immunodeficiency virus type (SIV(mac)) Gag capsid protein was introduced into Solanum tuberosum cells by Agrobacterium tumefaciens-mediated transformation methods. The gag gene was detected in the genomic DNA of transformed leaf tissues by PCR DNA amplification. Immunoblot analysis of transformed potato plant extracts with anti-Gag monoclonal antibody showed that biologically active Gag protein was synthesized in transformed tuber tissues. Based on ELISA results, recombinant Gag protein made up 0.006-0.014% of total soluble tuber protein. The synthesis of SIV Gag in transformed potato tubers opens the way for development of Gag-based edible plant vaccines for protection against SIV and potentially HIV-1 infection.
Subject(s)
AIDS Vaccines/isolation & purification , Capsid Proteins/isolation & purification , Gene Products, gag/isolation & purification , HIV Infections/prevention & control , SAIDS Vaccines/isolation & purification , Simian Acquired Immunodeficiency Syndrome/prevention & control , Simian Immunodeficiency Virus/genetics , AIDS Vaccines/genetics , Agrobacterium tumefaciens/genetics , Capsid Proteins/genetics , Gene Expression , Gene Products, gag/genetics , Humans , SAIDS Vaccines/genetics , Solanum tuberosum/geneticsABSTRACT
A non-human primate model for acquired immunodeficiency syndrome (AIDS), the simian immunodeficiency virus (SIV)-infected rhesus monkey, was used to explore the role of the AIDS virus-specific cytotoxic T-lymphocyte (CTL) response in disease pathogenesis. This CTL response was measured using the major histocompatibility complex (MHC) class I/peptide tetramer technology. Large numbers of tetramer-binding CD8+ T lymphocytes were demonstrable not only in the peripheral blood, but in lymph nodes and even in semen of chronically SIV-infected monkeys. The central role of these effector T lymphocytes in containing SIV spread during primary infection was demonstrated by showing that early SIV clearance during primary infection correlated with the emergence of the tetramer binding CD8+ T lymphocytes and that in vivo depletion of CD8+ lymphocytes eliminated the ability of the infected monkeys to contain SIV replication. These observations suggest that an effective AIDS vaccine should elicit a potent virus-specific CTL response. In fact, a live, recombinant SIV vaccine constructed using the attenuated pox virus vector modified vaccinia Ankara (MVA) elicited a high-frequency CTL response, comparable in magnitude to that elicited by SIV infection itself. This suggests that vaccine modalities such as MVA may prove useful in creating an effective human immunodeficiency virus (HIV) vaccine. These studies also indicate the power of both the SIV/macaque model and MHC class I/peptide tetramers for assessing AIDS vaccine strategies.